Nathan B Bowen

US Patent:

20180148486, May 31, 2018

Filed:

May 31, 2016

Appl. No.:

15/578165

Inventors:

- Atlanta GA, US
Nathan John Bowen - Atlanta GA, US

International Classification:

C07K 14/47
C12N 15/11
C12N 9/22
C12N 15/85

Abstract:

Human cell lines mutant for ZIC2 with altered cellular phenotype are disclosed, including HEK 293T, LN prostate cancer, and PC-3 cell lines. Method of making the human cell lines mutant for ZIC2 using gene editing tools such as CRISPR/Cas9 is also disclosed herein. Phenotypic characterization of the clonal mutant lines revealed altered cellular phenotypes relative to the parental lines. For example, ZIC2 protein expression is lost or lowered in these cell lines by western blot analyses. The human cell lines mutant for ZIC2 have various utilities including cancer diagnosis and prognosis.

US Patent:

20150125517, May 7, 2015

Filed:

Nov 12, 2014

Appl. No.:

14/539096

Inventors:

- Atlanta GA, US
Nathan John Bowen - Atlanta GA, US
LiJuan Wang - Smyrna GA, US

International Classification:

C12N 15/113
A61N 5/10
A61K 31/7105
A61K 45/06
A61K 9/51

US Classification:

424450, 514 44 A, 424497

Abstract:

The present invention provides a method of treating an ovarian cancer, the method comprising delivering one or more miR-200 family members to a mammalian subject in need thereof in an amount effective to treat the ovarian cancer. Also provided are methods of preventing metastasis of an ovarian cancer, the method comprising delivering one or more miR-200 family members to a mammalian subject in need thereof in an amount effective to prevent metastasis. Further provided are methods of sensitizing an ovarian cancer to a cytotoxic therapy, the method comprising delivering one or more miR-200 family members to a mammalian subject in need thereof in an amount effective to sensitize the ovarian cancer to the cytotoxic therapy. The invention also contemplates methods of reducing epithelial-to-mesenchymal transition (EMT) in an ovarian cancer or cancer cell as well as methods of inducing mesenchymal-to-epithelial transition (MET).